Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer Discovery|October 23, 2015
Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven LymphomaJennifer R Devlin, Katherine M Hannan, Nadine Hein, et al.
The EMBO Journal|September 18, 2020
Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesisEric P Kusnadi, Anna S Trigos, Carleen Cullinane, et al.
Molecular Cell|August 26, 2025
A CDK11-dependent RNA polymerase II pause-checkpoint precedes CDK9-mediated transition to transcriptional elongationJennifer R Devlin, Ben Martin, Nenad Bartonicek, et al.
Oncotarget|July 9, 2016
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingJaclyn Quin, Keefe T Chan, Jennifer R Devlin, et al.
Leukemia|December 13, 2019
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignanciesDarren C Phillips, Sha Jin, Gareth P Gregory, et al.
Science Advances|September 12, 2020
CDK13 cooperates with CDK12 to control global RNA polymerase II processivityZheng Fan, Jennifer R Devlin, Simon J Hogg, et al.
Blood|March 12, 2017
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationNadine Hein, Donald P Cameron, Katherine M Hannan, et al.
Cell Reports|June 2, 2026
An orally active dual CBP/p300 degrader targets core dependencies of multiple myelomaPraveen Kumar Tiwari, Bomin Ku, Drew A Harrison, et al.
Cell|May 18, 2021
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancerStephin J Vervoort, Sarah A Welsh, Jennifer R Devlin, et al.
Molecular Cell|May 21, 2021
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibitionSimon J Hogg, Olga Motorna, Leonie A Cluse, et al.
Pageof 2